title: Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
authors.forename: P T
authors.initials: PT
authors.lastname: Greipp
authors.forename: P
authors.initials: P
authors.lastname: Kapoor
authors.forename: W G
authors.initials: WG
authors.lastname: Morice
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.forename: P R
authors.initials: PR
authors.lastname: Greipp
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab